# V1 Empirics Check — openai/gpt-oss-120b (Variant B)

**Model:** openai/gpt-oss-120b
**Variant:** B
**Date:** 2026-03-31T10:10:19.683684

---

**1. Idea Fidelity**  

The paper follows the original manifest closely.  
- **Policy variation:** It uses the staggered state‑level opt‑out from the 2001 CMS physician‑supervision rule, matching the list of waves and the 22–25 treated states identified in the manifest.  
- **Data source:** The author relies on the Census Bureau Quarterly Workforce Indicators (QWI), exactly the “QWI Azure” panel described in the idea (state × quarter × education × 3‑digit NAICS).  
- **Identification strategy:** The baseline specification is a staggered DiD; the author augments it with the Callaway‑Sant’Anna (2021) and Sun‑Abraham (2021) estimators and a triple‑difference that subtracts hospital (NAICS 622) trends, as proposed in the manifest’s DDD design.  
- **Placebo groups:** The paper implements the two education‑group placebos (E1–E3 vs. E4) and the industry placebo (NAICS 623) that were part of the original plan.  

Overall, the manuscript does not miss any key component of the proposed research question, data, or identification approach.

---

**2. Summary**  

The paper investigates whether state opt‑outs from the federal Medicare supervision requirement for Certified Registered Nurse Anesthetists (CRNAs) altered the supply of advanced‑practice providers in ambulatory health‑care settings. Using a staggered DiD design with four modern estimators and several placebo checks on QWI data, the author finds precisely estimated null effects on employment, hiring, and earnings of BA‑plus workers in ambulatory care, suggesting that the supervision rule was not binding in practice.

---

**3. Essential Points**  

1. **Measurement of the CRNA‑Specific Workforce**  
   *Issue:* The treatment is expected to affect CRNAs, yet the outcome variable aggregates all workers with a bachelor’s degree or higher (E4) in NAICS 621, which also includes NPs, PAs and other advanced‑practice staff. If opt‑out leads to a reallocation *within* the E4 group, the aggregate effect could be muted, undermining the causal interpretation.  
   *Required:* Provide evidence that the E4 share in NAICS 621 is dominated by CRNAs (e.g., occupational‑code breakdowns from the BLS QCEW or an auxiliary data source). If that is not possible, discuss how potential compositional changes could generate a zero aggregate effect and, if feasible, re‑estimate using a subsample that isolates CRNAs (e.g., by linking QWI to the National Plan and Provider Enumeration System).

2. **Parallel‑Trends Evidence and Timing of Treatment**  
   *Issue:* The manuscript states that pre‑trend coefficients are “statistically insignificant,” but the event‑study figures are missing, and the pre‑period for early adopters is very short (1998‑2001). Moreover, the treatment definition uses the calendar year of opt‑out, while the QWI is quarterly; possible lagged implementation could bias the estimate.  
   *Required:* Include full event‑study plots for each cohort showing the leads (at least three pre‑quarters) and discuss whether any anticipatory effects are plausible. Conduct a robustness check that defines treatment as the quarter after the official opt‑out letter (or introduces a one‑quarter lag) to verify sensitivity.

3. **Interpretation of the Null Result and Policy Relevance**  
   *Issue:* The discussion attributes the null to “informal institutions” but provides limited direct evidence. The claim that the rule is merely ceremonial is strong and would benefit from corroborating institutional data (e.g., state credentialing policies, payer contracts, malpractice claims).  
   *Required:* Strengthen the argument by (i) presenting descriptive evidence that physician‑supervision requirements persisted post‑opt‑out in a sample of hospitals (e.g., via state hospital licensing surveys or CMS Condition of Participation compliance reports); or (ii) citing prior qualitative work that documents continued supervision practices. Without such evidence, the conclusion may be overstated.

If the authors cannot address any of these three points, the paper should be rejected; however, addressing them will likely make the contribution solid.

---

**4. Suggestions**  

- **Clarify the Treatment Variable**  
  - Explicitly list the exact date (month‑day) each state’s opt‑out became effective and show how this is mapped onto the quarterly QWI panel.  
  - Consider constructing a binary “treated” variable that turns on in the first full quarter after the opt‑out to avoid partial‑treatment contamination.

- **Provide Occupational Detail**  
  - Even if a full CRNA‑specific QWI series is unavailable, you can use the BLS Quarterly Census of Employment and Wages (QCEW) occupational codes (e.g., 29‑1061 – Anesthesiologists, 29‑1062 – Nurse Anesthetists) at the state‑year level to estimate the proportion of CRNAs among E4 workers. Present these shares in a table; if CRNAs constitute a sizable fraction (≥30 %), the aggregate measure is more defensible.  
  - If CRNAs are a small share, explore a two‑step approach: first estimate the effect on the E4 group, then use the occupational share to back‑out an implied CRNA effect, discussing the assumptions involved.

- **Expand the Event‑Study Presentation**  
  - Include separate event‑study graphs for (a) the primary outcome, (b) the earnings outcome, and (c) the placebo outcomes. Display confidence bands and annotate the adoption year for each cohort.  
  - Report joint tests of the pre‑trend coefficients (e.g., an F‑test that all leads are zero) to complement visual inspection.

- **Robustness to Alternative Clustering and Inference**  
  - With 51 clusters, conventional cluster‑robust SEs are borderline. Add robustness checks using wild‑cluster bootstrap or the CV\(_{3}\) correction (Cameron, Gelbach, Miller, 2008) and report whether inference changes.  
  - Consider a spatial correlation check (e.g., Moran’s I) to ensure that nearby states do not share unobserved shocks that could violate the independence assumption.

- **Alternative Control Groups**  
  - The manuscript uses never‑treated states as controls. As an additional sanity check, implement the “synthetic control” approach for a few early adopters (e.g., Iowa, California) to verify that the DiD results are not driven by differential pre‑trends.  
  - Also, construct a “within‑state” control using another health‑care subsector that is less likely to be affected by anesthesia supervision (e.g., dental services, NAICS 6212) to further guard against common shocks.

- **Placebo Tests with Different Lags**  
  - The current placebos compare non‑BA workers and a different industry in the same period. Strengthen them by (i) shifting the placebo treatment forward/backward by one quarter and confirming that the coefficient remains null; (ii) applying the same DDD framework to a sector where no effect is expected (e.g., retail) to show the method does not generate spurious findings.

- **Address Potential Heterogeneity**  
  - The “Leave‑One‑Wave‑Out” table is useful, but you could go further by interacting the treatment with (a) the share of CRNAs in the state’s labor force pre‑treatment, (b) rurality (e.g., percent of population living in non‑metro counties), or (c) the baseline physician‑to‑CRNA ratio. This would test whether the policy mattered in the most constrained markets, aligning with the paper’s motivation about rural shortages.

- **Discussion of Power and Minimum Detectable Effects**  
  - While the paper notes that the confidence interval rules out “large” effects, it would be helpful to compute the minimum detectable effect (MDE) given the sample size, variance, and cluster count. Present this as a table, and discuss whether the MDE is economically meaningful (e.g., “we can rule out a ≥5 % increase in ambulatory employment”).

- **Minor Presentation Issues**  
  - The abstract mentions “22 states between 2001 and 2022,” whereas the manifest cites 25+ states up to 2024. Clarify the exact sample and justify any exclusion of later adopters.  
  - Table 1’s standard deviations look unusually large (e.g., SD of employment > mean). Verify that the numbers are correctly reported (perhaps they are quarterly totals, not averages).  
  - Consistently label the dependent variable as “log employment” (or “log E”) throughout the text to avoid confusion with the raw level.  
  - Add a short paragraph on why the alternative “hospital” outcome (NAICS 622) is appropriate as a within‑state control; cite literature that uses industry controls in health‑care DiD studies.

- **Policy Implications and Future Work**  
  - The conclusion could be expanded to discuss alternative levers for expanding CRNA‑driven capacity (e.g., changes to credentialing rules, reimbursement reforms). Suggest a research agenda that combines the current quantitative approach with qualitative case studies of hospitals that did/ did not change supervision practices after opt‑out.

Implementing these suggestions will tighten the causal story, bolster the credibility of the null finding, and make the paper a more compelling contribution to the health‑care labor‑market literature.
